Munetaka Takekuma, Mototsugu Shimokawa, Shin Nishio, Hideo Omi, Tsutomu Tabata, Yuji Takei, Kaei Nasu, Yoshiyuki Takahashi, Shinji Toyota, Yoshikazu Ichikawa, Atsushi Arakawa, Fuminori Ito, Hiroshi Tsubamoto, Taisuke Mori, Yasuyuki Hirashima, Kimihiko Ito
The purpose of this phase II trial was to assess the efficacy and toxicity of paclitaxel and nedaplatin (TN) as the initial postoperative adjuvant chemotherapy for uterine cervical cancer with lymph node metastases (LNM). Patients with FIGO stage IB1-IIA2 squamous cell carcinoma of the uterine cervix were enrolled. Histological confirmation of LNM was mandatory. Intravenous paclitaxel at 175 mg/m2 and nedaplatin at 80 mg/m2 were administered every 28-day cycle, of which there were five cycles after radical hysterectomy...
March 25, 2018: Cancer Science